These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 37478574)

  • 1. Neoadjuvant PD-1/PD-L1 inhibitors combined with chemotherapy had a higher ORR than mono-immunotherapy in untreated HNSCC: Meta-analysis.
    Chen S; Yang Y; Wang R; Fang J
    Oral Oncol; 2023 Oct; 145():106479. PubMed ID: 37478574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant PD-1/PD-L1 Inhibitors for Resectable Head and Neck Cancer: A Systematic Review and Meta-analysis.
    Masarwy R; Kampel L; Horowitz G; Gutfeld O; Muhanna N
    JAMA Otolaryngol Head Neck Surg; 2021 Oct; 147(10):871-878. PubMed ID: 34473219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
    Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
    Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.
    Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X
    Front Immunol; 2021; 12():645170. PubMed ID: 33897693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-1/PD-L1 inhibitor plus chemotherapy versus standard of care in the first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma.
    Mo DC; Huang JF; Luo PH; Chen L; Zou B; Wang HL
    Eur Arch Otorhinolaryngol; 2023 Jan; 280(1):1-9. PubMed ID: 35907001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The current advances and future directions of PD-1/PD-L1 blockade in head and neck squamous cell carcinoma (HNSCC) in the era of immunotherapy.
    Chen Y; Ding X; Bai X; Zhou Z; Liu Y; Zhang X; Yu J; Hu M
    Int Immunopharmacol; 2023 Jul; 120():110329. PubMed ID: 37207445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors: A meta-analysis based on clinical trials.
    Huang Z; Zheng S; Ding S; Wei Y; Chen C; Liu X; Li H; Xia Y
    J Cancer Res Ther; 2021 Jul; 17(3):676-687. PubMed ID: 34269299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1/PD-L1 inhibitors in real-world head and neck and lung cancer patients.
    Foy JP; Karabajakian A; Ortiz-Cuaran S; Boussageon M; Michon L; Bouaoud J; Fekiri D; Robert M; Baffert KA; Hervé G; Quilhot P; Attignon V; Girod A; Chaine A; Benassarou M; Zrounba P; Caux C; Ghiringhelli F; Lantuejoul S; Crozes C; Brochériou I; Pérol M; Fayette J; Bertolus C; Saintigny P
    Eur J Cancer; 2022 Oct; 174():287-298. PubMed ID: 36038492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
    Ghanizada M; Jakobsen KK; Grønhøj C; von Buchwald C
    Oral Oncol; 2019 Mar; 90():67-73. PubMed ID: 30846179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma.
    Wang J; Sun H; Zeng Q; Guo XJ; Wang H; Liu HH; Dong ZY
    Sci Rep; 2019 Sep; 9(1):13404. PubMed ID: 31527697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-PD-1 and Anti-PD-L1 in Head and Neck Cancer: A Network Meta-Analysis.
    Botticelli A; Cirillo A; Strigari L; Valentini F; Cerbelli B; Scagnoli S; Cerbelli E; Zizzari IG; Rocca CD; D'Amati G; Polimeni A; Nuti M; Merlano MC; Mezi S; Marchetti P
    Front Immunol; 2021; 12():705096. PubMed ID: 34434192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
    Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
    Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination immunochemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: a systematic review and meta-analysis.
    Xu Q; Huang S; Yang K
    BMJ Open; 2023 Jun; 13(6):e069047. PubMed ID: 37311638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer.
    Qiao XW; Jiang J; Pang X; Huang MC; Tang YJ; Liang XH; Tang YL
    Front Immunol; 2020; 11():1721. PubMed ID: 33072064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with immune checkpoint inhibitors in recurrent or metastatic squamous cell carcinoma of the head and neck: A meta-analysis.
    Chen L; Mo DC; Hu M; He W; Yang QW; Tang J
    Int Immunopharmacol; 2023 Jun; 119():110270. PubMed ID: 37150013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advanced Driver-Gene Wild-Type Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
    Xu Q; Zhang X; Huang M; Dai X; Gao J; Li S; Sheng L; Huang K; Wang J; Liu L
    Front Immunol; 2021; 12():731546. PubMed ID: 34484242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma.
    Starzer AM; Heller G; Tomasich E; Melchardt T; Feldmann K; Hatziioannou T; Traint S; Minichsdorfer C; Schwarz-Nemec U; Nackenhorst M; Müllauer L; Preusser M; Berghoff AS; Fuereder T
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of cetuximab plus PD-1 inhibitor differs by HPV status in head and neck squamous cell carcinoma: a systematic review and meta-analysis.
    Zhang S; Zheng M; Nie D; Xu L; Tian H; Wang M; Liu W; Feng Z; Han F
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36253001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.